3rd Quarter - Termination
AMYLIN PHARMACEUTICALS for AMYLIN PHARMACEUTICALS
Client
Income
—
Expenses
$170,000
Expense method
A: Lobbying Disclosure Act definitions
Terminated
Aug 31, 2012
What was lobbied
4 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Issues related to prevention, diagnosis and treatment of diabetes
| Lobbyist | Covered position, as disclosed |
|---|---|
| CRAIG BURTON | — |
| WILLIAM A FRANCO | — |
Medicare/Medicaid MMM
Issues relating to Medicare Part D rebates
| Lobbyist | Covered position, as disclosed |
|---|---|
| CRAIG BURTON | — |
| WILLIAM A FRANCO | — |
Budget/Appropriations BUD
FDA funding and agency effectiveness Potential Super Committee legislation affecting Medciare Part D and Medicaid rebates
| Lobbyist | Covered position, as disclosed |
|---|---|
| CRAIG BURTON | — |
| WILLIAM A FRANCO | — |
Pharmacy PHA
Perscription Drug User Fee Act Reauthorization FDA funding and agency effectiveness Drug importation issues Safeguarding America's Pharmaceuticals Act of 2011- H.R. 3026
| Lobbyist | Covered position, as disclosed |
|---|---|
| CRAIG BURTON | — |
| WILLIAM A FRANCO | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.